Bicycle Therapeutics to Present at ELRIG’s Research & Innovation 2019 Conference

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle
Therapeutics, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle™)
product platform, announced today that Paul Beswick, Ph.D., Bicycle’s
Director of UK Chemistry and IP, will present at the Research &
Innovation 2019 conference sponsored by the European Laboratory Research
& Innovation Group (ELRIG) in Cambridge, U.K. The presentation,
showcasing Bicycles as an entirely new class of therapeutics,
will take place on Wednesday, April 3, at 14:45 BST.

“Bicycles are a unique therapeutic modality, combining the pharmacology
usually associated with a biologic and the manufacturing and
pharmacokinetic properties of a small molecule,” said Nicholas Keen,
Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “Our technology
has great potential both in the field of oncology and more broadly, and
we’re excited to share our work at this ELRIG conference.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a unique class of chemically
synthesized medicines based on its proprietary bicyclic peptide (Bicycle™)
product platform to address therapeutic needs unreachable with existing
treatment modalities. Bicycle’s internal focus is in oncology, where the
company is developing targeted cytotoxics (Bicycle Toxin Conjugates™),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and
highly selective targeting deliver rapid tumor penetration and retention
while clearance rates and routes of elimination can be tuned to minimize
exposure of healthy tissue and bystander toxicities. The company’s lead
program, BT1718, is being evaluated in a Phase I/IIa trial in
collaboration with Cancer Research UK. The company’s unique intellectual
property is based on the work initiated at the MRC Laboratory of
Molecular Biology in Cambridge, U.K., by the scientific founders of the
company, Sir Greg Winter, a winner of the Nobel Prize in Chemistry for
his pioneering work in phage display of peptides and antibodies, and
Professor Christian Heinis. Bicycle has its headquarters in Cambridge,
U.K., with many key functions and members of its leadership team located
in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com or
follow us on Twitter at @Bicycle_tx.

Contacts

Media:
Ten Bridge Communications
Sara Green
[email protected]
+1-617-233-1714

Investors:
Argot Partners
Maeve Conneighton
[email protected]
+1-212-600-1902